Liraglutide and renal outcomes in type 2 diabetes

New England Journal of Medicine

Volumn 377, Issue 9, 2017, Pages 839-848

  Mann, Johannes F E ^a,b   Ørsted, David D ^c   Brown Frandsen, Kirstine ^c   Marso, Steven P ^d   Poulter, Neil R ^e   Rasmussen, Søren ^c   Tornøe, Karen ^c   Zinman, Bernard ^f   Buse, John B ^g  

^a KfH Kidney Center   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c NOVO NORDISK A S   (Denmark)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f MOUNT SINAI HOSPITAL   (Canada)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; CREATININE; GLUCAGON LIKE PEPTIDE 1;

ACUTE KIDNEY FAILURE; ADULT; ALBUMINURIA; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DISEASE COURSE; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; ACUTE KIDNEY INJURY; AGED; AGONISTS; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MORTALITY;

ACUTE KIDNEY INJURY; AGED; ALBUMINURIA; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE, CHRONIC; LIRAGLUTIDE; MALE; MIDDLE AGED;

EID: 85028547742     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1616011     Document Type: Article

References (31)

1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33.
2. Alegre-Díaz J, Herrington W, López-Cervantes M, et al. Diabetes and cause-specific mortality in Mexico City. N Engl J Med 2016;375:1961-71.
3. Molitch ME, Adler AI, Flyvbjerg A, et al. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int 2015;87:20-30.
4. Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2012;172:761-9.
5. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013;83:517-23.
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.
7. UK Prospect ive Diabetes St udy (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
8. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline. Ann Intern Med 2013;158: 825-30.
9. Zeisberg M, Zeisberg EM. Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin. Kidney Int 2015;88:429-31.
10. Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 2014;85:579-89.
11. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.
12. von Scholten BJ, Lajer M, Goetze JP, Persson F, Rossing P. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med 2015;32:343-52.
13. Skov J, Pedersen M, Holst JJ, et al. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab 2016;18:581-9.
14. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.
15. Marso SP, Poulter NR, Nissen SE, et al. Design of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. Am Heart J 2013;166(5):823-30.e5.
16. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function — measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-83.
17. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380:1662-73.
18. Schmieder RE, Mann JF, Schumacher H, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22:1353-64.
19. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813-21.
20. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-6.
21. Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 2017;91:683-90.
22. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year followup of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
23. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
24. Zoungas S, Woodward M, Li Q, et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia 2014;57:2465-74.
25. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42.
26. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
27. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35.
28. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57.
29. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
30. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its antiinflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965-78.
31. von Scholten BJ, Persson F, Rosenlund S, et al. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab 2017;19:901-5.